Related Experiment Video
Updated: Jun 3, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from
Kazem Rahimi1, Jonathan Emberson, Paul McGale
1George Centre for Healthcare Innovation, University of Oxford, Oxford, UK. kazem.rahimi@cardiov.ox.ac.uk
Objective:
To examine whether statins can reduce the risk of atrial fibrillation.
Design:
Meta-analysis of published and unpublished results from larger scale statin trials, with comparison of the findings against the published results from smaller scale or shorter duration studies.
Data Sources:
Medline, Embase, and Cochrane's CENTRAL up to October 2010. Unpublished data from longer term trials were obtained through contact with investigators.
Study Selection:
Randomised controlled trials comparing statin with no statin or comparing high dose versus standard dose statin; all longer term trials had at least 100 participants and at least six months' follow-up.
Results:
In published data from 13 short term trials (4414 randomised patients, 659 events), statin treatment seemed to reduce the odds of an episode of atrial fibrillation by 39% (odds ratio 0.61, 95% confidence interval 0.51 to 0.74; P < 0.001), but there was significant heterogeneity (P < 0.001) between the trials. In contrast, among 22 longer term and mostly larger trials of statin versus control (105,791 randomised patients, 2535 events), statin treatment was not associated with a significant reduction in atrial fibrillation (0.95, 0.88 to 1.03; P = 0.24) (P<0.001 for test of difference between the two sets of trials). Seven longer term trials of more intensive versus standard statin regimens (28,964 randomised patients and 1419 events) also showed no evidence of a reduction in the risk of atrial fibrillation (1.00, 0.90 to 1.12; P = 0.99).
Conclusions:
The suggested beneficial effect of statins on atrial fibrillation from published shorter term studies is not supported by a comprehensive review of published and unpublished evidence from larger scale trials.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
